Leo gets rights to two AZ dermatology candidates

AstraZeneca plc (LSE:AZN; NYSE:GSK) granted Leo Pharma A/S (Ballerup, Denmark) exclusive, global rights to tralokinumab ( CAT-354) for dermatological indications and European rights to brodalumab (

Read the full 264 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE